ISM001-055 showed dose-dependent improvements in FVC, with the highest dose group achieving significant gains compared to placebo. The trial confirmed the drug's tolerability, with mild to moderate ...
ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. Preliminary results from ...
Insilico Medicine announced results from a clinical trial of ISM001-055, which the company designed using generative AI in order to treat idiopathic pulmonary fibrosis, a chronic lung disease ...
Some say that AI’s potential in drug development is overstated. Others say that it is, if anything, understated. Who is right? Only time will tell. In the meantime, both sides—and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results